349 related articles for article (PubMed ID: 22469128)
1. Genetic heterogeneity and cancer drug resistance.
Turner NC; Reis-Filho JS
Lancet Oncol; 2012 Apr; 13(4):e178-85. PubMed ID: 22469128
[TBL] [Abstract][Full Text] [Related]
2. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
Gerlinger M; Swanton C
Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
[TBL] [Abstract][Full Text] [Related]
3. Tumour heterogeneity and resistance to cancer therapies.
Dagogo-Jack I; Shaw AT
Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304
[TBL] [Abstract][Full Text] [Related]
4. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
Venkatesan S; Swanton C; Taylor BS; Costello JF
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
[TBL] [Abstract][Full Text] [Related]
5. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Marusyk A; Janiszewska M; Polyak K
Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271
[TBL] [Abstract][Full Text] [Related]
6. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.
Lim ZF; Ma PC
J Hematol Oncol; 2019 Dec; 12(1):134. PubMed ID: 31815659
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics.
Bradford R; Koppel H; Pilkington GJ; Thomas DG; Darling JL
J Neurooncol; 1997 Sep; 34(3):247-61. PubMed ID: 9258817
[TBL] [Abstract][Full Text] [Related]
8. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
Lee AJ; Swanton C
Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
[TBL] [Abstract][Full Text] [Related]
9. Tumour heterogeneity and the evolution of polyclonal drug resistance.
Burrell RA; Swanton C
Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
[TBL] [Abstract][Full Text] [Related]
10. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A; Melchor L; Cavo M; Morgan GJ
Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
[TBL] [Abstract][Full Text] [Related]
11. Intra-tumour heterogeneity - going beyond genetics.
Caiado F; Silva-Santos B; Norell H
FEBS J; 2016 Jun; 283(12):2245-58. PubMed ID: 26945550
[TBL] [Abstract][Full Text] [Related]
12. Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma.
Fattore L; Ruggiero CF; Liguoro D; Mancini R; Ciliberto G
Cell Death Dis; 2019 Oct; 10(11):827. PubMed ID: 31672982
[TBL] [Abstract][Full Text] [Related]
13. Treatment resistance in urothelial carcinoma: an evolutionary perspective.
Vlachostergios PJ; Faltas BM
Nat Rev Clin Oncol; 2018 Aug; 15(8):495-509. PubMed ID: 29720713
[TBL] [Abstract][Full Text] [Related]
14. A new model isolates glioblastoma clonal interactions and reveals unexpected modes for regulating motility, proliferation, and drug resistance.
Davis JB; Krishna SS; Abi Jomaa R; Duong CT; Espina V; Liotta LA; Mueller C
Sci Rep; 2019 Nov; 9(1):17380. PubMed ID: 31758030
[TBL] [Abstract][Full Text] [Related]
15. Addressing intra-tumoral heterogeneity and therapy resistance.
Rybinski B; Yun K
Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
[TBL] [Abstract][Full Text] [Related]
16. Resisting Resistance: Targeted Therapies in Lung Cancer.
Lin JJ; Shaw AT
Trends Cancer; 2016 Jul; 2(7):350-364. PubMed ID: 27819059
[TBL] [Abstract][Full Text] [Related]
17. Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability.
Guenot D; Guérin E; Aguillon-Romain S; Pencreach E; Schneider A; Neuville A; Chenard MP; Duluc I; Du Manoir S; Brigand C; Oudet P; Kedinger M; Gaub MP
J Pathol; 2006 Apr; 208(5):643-52. PubMed ID: 16450341
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer intratumor genetic heterogeneity: causes and implications.
Ng CK; Pemberton HN; Reis-Filho JS
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1021-32. PubMed ID: 23030222
[TBL] [Abstract][Full Text] [Related]
19. Clonal cooperativity in heterogenous cancers.
Zhou H; Neelakantan D; Ford HL
Semin Cell Dev Biol; 2017 Apr; 64():79-89. PubMed ID: 27582427
[TBL] [Abstract][Full Text] [Related]
20. Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine.
Aleskandarany MA; Vandenberghe ME; Marchiò C; Ellis IO; Sapino A; Rakha EA
Pathobiology; 2018; 85(1-2):23-34. PubMed ID: 29428954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
